









Markets
/
Stocks
/
nasdaq-acxp
/

Acurx Pharmaceuticals Inc

ACXP

4.100USD

-0.240-5.53%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

301.42KMarket Cap

LossP/E TTM



Acurx Pharmaceuticals Inc

4.100

-0.240-5.53%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

258 / 506

Overall Ranking

417 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

61.700

Target Price

+1321.66%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 16.62.

Overvalued

The company’s latest PE is -0.05, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 306.40K shares, increasing 18.30% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 7.28K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.88.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.05, which is 2878.80% below the recent high of -1.49 and -5376.60% above the recent low of -2.74.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 258/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Acurx Pharmaceuticals Inc is 30.50, with a high of 165.80 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

61.700

Target Price

+1321.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Acurx Pharmaceuticals Inc

ACXP

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.83, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 6.38 and the support level at 3.06, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.83

Change

-0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.240

Neutral

RSI(14)

51.674

Neutral

STOCH(KDJ)(9,3,3)

24.288

Sell

ATR(14)

0.362

Low Volatility

CCI(14)

71.793

Neutral

Williams %R

82.236

Oversold

TRIX(12,20)

0.369

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

4.180

Sell

MA10

4.186

Sell

MA20

4.385

Sell

MA50

3.136

Buy

MA100

1.783

Buy

MA200

1.218

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 22.51%, representing a quarter-over-quarter decrease of 15.28%. The largest institutional shareholder is The Vanguard, holding a total of 7.28K shares, representing 0.46% of shares outstanding, with 85.23% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Luci (David P)

1.15M

DeLuccia (Robert J)

1.01M

Prospect Financial Services LLC

366.58K

+11.40%

Shawah (Robert G)

189.20K

Geode Capital Management, L.L.C.

171.49K

+17.06%

The Vanguard Group, Inc.

Star Investors

529.35K

Sailer (Carl)

142.18K

Morgan Stanley Smith Barney LLC

106.20K

Renaissance Technologies LLC

Star Investors

26.60K

+81.27%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.98, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -1.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.